Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C

NAUnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
OTHER

ARM A

30 IBS-C patients will receive GA-AT0119 for 28 days, followed by a washout period of 28 days and Placebo for another 28 days

OTHER

ARM B

30 IBS-C patients will receive Placebo for 28 days, followed by a washout period of 28 days and GA-AT0119 for another 28 days

Trial Locations (4)

Unknown

RECRUITING

Outpatient clinic for individual practice for primary medical care Dr. Elenski EOOD, Plovdiv

RECRUITING

Medical Center Prolet EOOD, Rousse

ACTIVE_NOT_RECRUITING

Medical Center Prolet EOOD, Rousse

RECRUITING

Ambulatory Practice for Primary Outpatient Medical Care SANA OOD, Sofia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CEBIS International

OTHER

lead

Devintec Sagl

INDUSTRY

NCT05240521 - Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C | Biotech Hunter | Biotech Hunter